Dr. Reddy's Laboratories is a global pharmaceutical company based in India that focuses on the development, manufacturing, and marketing of a wide range of healthcare products
The company specializes in generic medications, active pharmaceutical ingredients, and proprietary formulations, catering to various therapeutic areas such as oncology, cardiovascular, and pain management. Dr. Reddy's is committed to improving access to quality medicine for patients around the world and engages in research and development to innovate and advance healthcare solutions. Through its extensive portfolio, the company contributes to both the pharmaceutical market and public health initiatives.
Shanghai Multitude Therapeutics out-licensed global rights for its Tissue Factor ADC to Adcendo in a $1 billion agreement. The value of the agreement includes upfront and milestone payments, with potential royalties on sales also available.
Haleon has agreed to sell its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories SA for £500 million ($632 million). This strategic move allows Haleon to focus on growth areas.
RDY stock results show that Dr Reddy's Laboratories beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024.
Indian pharmaceutical giants, including Sun Pharma and Cipla, seize the opportunity to develop affordable versions of Novo Nordisk's Wegovy weight-loss treatment. With patents set to expire by 2026-2032, these generics aim to address India's rising obesity and diabetes concerns, anticipating substantial market growth in the next decade.
Journey Medical Corporation (NASDAQDERM) shares are trading lower after the company announced topline results from the two Phase 3 trials, evaluating Minocycline Hydrochloride Modified Release Capsules (DFD-29) for adult patients with moderate-to-severe
